Stroke prevention - Narrowing the evidence-practice gap

被引:87
作者
Holloway, RG [1 ]
Benesch, C
Rush, SR
机构
[1] Univ Rochester, Sch Med & Dent, Dept Neurol, Rochester, NY 14642 USA
[2] Univ Rochester, Sch Med & Dent, Dept Community & Prevent Med, Rochester, NY 14642 USA
[3] Amer Acad Neurol, Dept Qual Improvement, St Paul, MN USA
关键词
stroke; prevention; risk factors; health services;
D O I
10.1212/WNL.54.10.1899
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Many interventions reduce stroke risk. However, the full benefits of these interventions are not realized at current levels of utilization, as nearly all evidence-based or guideline-endorsed stroke prevention services are underused. The cause for such underuse is multifactorial and includes factors relating to both patients and providers, as well as to a health care system that has de-emphasized prevention at the expense of acute, technologically based care. Much like the evidence for stroke interventions themselves, there is a growing literature to support methods of implementing research evidence into clinical practice. There is still much to learn, however, about the effectiveness of interventions aimed at achieving changes in stroke prevention practice or the delivery of stroke prevention care. Nevertheless, there are many opportunities for providers, managed care organizations, and government to close the evidence-practice gap that exists for stroke prevention services. These opportunities exist in both the inpatient and outpatient setting, and depend on the neurologist taking a leading role in emphasizing the critical importance of risk factor identification and modification in all patients at risk for stroke.
引用
收藏
页码:1899 / 1906
页数:8
相关论文
共 56 条
  • [1] *ACCR COUNC GRAD M, 1998, GRAD MED ED DIR 1998
  • [2] Allen H, 1998, Br J Nurs, V7, P1252
  • [3] COLLABORATIVE OVERVIEW OF RANDOMIZED TRIALS OF ANTIPLATELET THERAPY .1. PREVENTION OF DEATH, MYOCARDIAL-INFARCTION, AND STROKE BY PROLONGED ANTIPLATELET THERAPY IN VARIOUS CATEGORIES OF PATIENTS
    ALTMAN, R
    CARRERAS, L
    DIAZ, R
    FIGUEROA, E
    PAOLASSO, E
    PARODI, JC
    CADE, JF
    DONNAN, G
    EADIE, MJ
    GAVAGHAN, TP
    OSULLIVAN, EF
    PARKIN, D
    RENNY, JTG
    SILAGY, C
    VINAZZER, H
    ZEKERT, F
    ADRIAENSEN, H
    BERTRANDHARDY, JM
    BRAN, M
    DAVID, JL
    DRICOT, J
    LAVENNEPARDONGE, E
    LIMET, R
    LOWENTHAL, A
    MORIAU, M
    SCHAPIRA, S
    SMETS, P
    SYMOENS, J
    VERHAEGHE, R
    VERSTRAETE, M
    ATALLAH, A
    BARNETT, H
    BATISTA, R
    BLAKELY, J
    CAIRNS, JA
    COTE, R
    CROUCH, J
    EVANS, G
    FINDLAY, JM
    GENT, M
    LANGLOIS, Y
    LECLERC, J
    NORRIS, J
    PINEO, GF
    POWERS, PJ
    ROBERTS, R
    SCHWARTZ, L
    SICURELLA, J
    TAYLOR, W
    THEROUX, P
    [J]. BMJ-BRITISH MEDICAL JOURNAL, 1994, 308 (6921): : 81 - 100
  • [4] [Anonymous], DIABETES CARE
  • [5] [Anonymous], 1996, GUID CLIN PREV SERV
  • [6] [Anonymous], 1998, Getting research findings into practice
  • [7] Consensus guidelines for coordinated outpatient oral anticoagulation therapy management
    Ansell, JE
    Buttaro, ML
    Thomas, IV
    Knowlton, CH
    Becker, DM
    Bussey, HI
    Corey, R
    Gums, JG
    Hughes, R
    Jacobson, A
    Kirchain, W
    Kuhn, K
    Loken, S
    McCain, J
    Haley, JA
    Oertel, LB
    Thrasher, K
    Triplett, DA
    Whitcomb, H
    Wittkowsky, AK
    Zarus, SA
    [J]. ANNALS OF PHARMACOTHERAPY, 1997, 31 (05) : 604 - 615
  • [8] Asplund K, 1997, BMJ-BRIT MED J, V314, P1151
  • [9] BALAS EA, 2000, ARCH FAM MED, V5, P271
  • [10] Warfarin use among patients with atrial fibrillation
    Brass, LM
    Krumholz, HM
    Scinto, JM
    Radford, M
    [J]. STROKE, 1997, 28 (12) : 2382 - 2389